ArticleEuropean urology open science2025
National Trends in Medication Prescriptions for Male Lower Urinary Tract Symptoms and Erectile Dysfunction: Findings from the Norwegian Prescription Database.
Article in European urology open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Target and off-target effects of vibegron on smooth muscle contraction of human detrusor and prostate tissues.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Analysis of functional urological surgery trends 2013-2024 in England using the HES database.World journal of urology · 2026Article
- Transurethral resection of the prostate in the extreme elderly (≥ 85 years): treatment success, morbidity and survival.World journal of urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Trends for the medical management of male lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) remain-under reported at a national level. Our aim was to analyse national trends in prescribing patterns for ED and LUTS medications among men in Norway. Methods: Data were extracted from the Norwegian Prescription Database (Norwegian Institute of Public Health) for the period 2004-2020. Medications were identified according to the Anatomical Therapeutic Chemical classification system. Key findings and limitations: For BPH medications collectively, the total annual number of prescriptions increased from 23 711 in 2014 to 102 531 in 2020. α-Adrenoceptor antagonists were prescribed five times more often than 5α-reductase inhibitors. Ten in 100 men aged ≥75 yr now receive a prescription for a BPH medication. By 2020, 19 per 1000 men received a prescription for ED medication. Sildenafil was the most popular choice (47%), followed by tadalafil (43%) and vardenafil (4.8%); the number of users per 1000 men increased from 4.4 to 9.3. Among medications used for urinary incontinence/urgency, mirabegron was the most popular choice (62%) in 2020, followed by oxybutynin (17%). Conclusions and clinical implications: Prescriptions for medications for BPH, ED, and urinary incontinence/frequency have increased at a national level. Further studies are needed to link this with individual data to ascertain discontinuation rates and conversion from pharmacotherapy to surgical intervention. Patient summary: In Norway, there were increasing trends in the use of medications to treat benign prostate enlargement (BPE), erectile dysfunction, and urinary incontinence between 2004 and 2020. The biggest rise was for medications for BPE, which are now prescribed more often than for medications for erectile dysfunction. In recent years, the number of surgeries performed for BPE has fallen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.